Intravenous immunoglobulin therapy in pediatric narcolepsy: A nonrandomized, open-label, controlled, longitudinal observational study

Journal of Clinical Sleep Medicine

Volumn 13, Issue 3, 2017, Pages 441-453

  Lecendreux, Michel ^a,b   Berthier, Johanna ^c   Corny, Jennifer ^a   Bourdon, Olivier ^a,d   Dossier, Claire ^a   Delclaux, Christophe ^a,d  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b National Reference Centre for Orphan Diseases Narcolepsy Idiopathic hypersomnia and Kleine Levin Syndrome (CNR Narcolepsie Hypersomnie)   (France)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cataplexy; Child; Immunoglobulin; Immunomodulation; Narcolepsy

Indexed keywords

HLA DQB1 ANTIGEN; IMMUNOGLOBULIN; OREXIN; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHILD; CHILD AND ADOLESCENT SLEEPINESS SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; NARCOLEPSY; OBSERVATIONAL STUDY; OPEN STUDY; PEDIATRIC DAYTIME SLEEPINESS SCALE; RATING SCALE; REMISSION; RETROSPECTIVE STUDY; SLEEP; TREATMENT RESPONSE; ULLANLINNA NARCOLEPSY SCALE; FRANCE; TREATMENT OUTCOME;

CHILD; FEMALE; FRANCE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; NARCOLEPSY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85015996736     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.6500     Document Type: Article

References (39)

1. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
2. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
3. Inocente CO, Lavault S, Lecendreux M, et al. Impact of obesity in children with narcolepsy. CNS Neurosci Ther. 2013;19(7):521-528.
4. Inocente CO, Gustin M-P, Lavault S, et al. Depressive feelings in children with narcolepsy. Sleep Med. 2014;15(3):309-314.
5. Lecendreux M, Lavault S, Lopez R, et al. Attention-deficit/hyperactivity disorder (ADHD) symptoms in pediatric narcolepsy: a cross-sectional study. Sleep. 2015;38(8):1285-1295.
6. Inocente CO, Gustin MP, Lavault S, et al. Quality of life in children with narcolepsy. CNS Neurosci Ther. 2014;20(8):763-771.
7. Hayes D, Jr. Narcolepsy with cataplexy in early childhood. Clin Pediatr (Phila). 2006;45(4):361-363.
8. Stores G, Montgomery P, Wiggs L. The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin. Pediatrics. 2006;118(4):e1116-e1123.
9. Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51-61.
10. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010;120(3):713-719.
11. Kawashima M, Lin L, Tanaka S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010;33(7):869-874.
12. Toyoda H, Tanaka S, Miyagawa T, Honda Y, Tokunaga K, Honda M. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep. 2010;33(7):875-878.
13. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013;136(Pt 8):2486-2496.
14. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One. 2012;7(3):e33723.
15. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70(3):410-417.
16. Heier MS, Gautvik KM, Wannag E, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med. 2013;14(9):867-871.
17. Ahmed SS, Volkmuth W, Duca J, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med. 2015;7(294):294ra105.
18. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol. 2006;60(1):153.
19. Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol. 2004;56(6):905-908.
20. Lecendreux M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003;12(4):347-348.
21. Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol. 2008;255(10):1549-1554.
22. Valko PO, Khatami R, Baumann CR, Bassetti CL. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol. 2008;255(12):1900-1903.
23. Zuberi SM, Mignot E, Ling L, McArthur I. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy [Abstracts of the ESRS, Prague 2004]. J Sleep Res. 2014;13(Suppl 1):828.
24. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol. 2005;58(3):489-490.
25. Knudsen S, Biering-Sorensen B, Kornum BR, et al. Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology. 2012;79(1):102-103.
26. Donjacour CE, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res. 2011;21(4):479-480.
27. Hersh CM, Cohen JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy. 2014;6(3):249-259.
28. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;9:CD002063.
29. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003(4):CD004000.
30. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2014;54(1):108-115.
31. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000;320(7244):1240-1243.
32. Rolland-Cachera MF. Childhood obesity: current definitions and recommendations for their use. Int J Pediatr Obes. 2011;6(5-6):325-331.
33. Hublin C, Kaprio J, Partinen M, Koskenvuo M, Heikkila K. The Ullanlinna narcolepsy scale: validation of a measure of symptoms in the narcoleptic syndrome. J Sleep Res. 1994;3(1):52-59.
34. Drake C, Nickel C, Burduvali E, Roth T, Jefferson C, Pietro B. The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep. 2003;26(4):455-458.
35. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.
36. Olmos A, Govindasamy P. A practical guide for using propensity score weighting in R. Practical Assessment, Research & Evaluation. 2015;20(13):1-8.
37. Guo Z, Gill TM, Allore HG. Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med. 2008;47(2):107-116.
38. Pizza F, Franceschini C, Peltola H, et al. Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain. 2013;136(Pt 12):3787-3795.
39. Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy. Sleep. 2010;33(11):1428-1430.